Henry Schein Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Henry Schein şirketinin kazançları yıllık ortalama -5.9% oranında azalırken, Healthcare sektörünün kazançları yıllık 31.3% oranında artan oldu. Gelirler yıllık ortalama 6.4% oranında artan oldu. Henry Schein şirketinin öz sermaye getirisi 7.3% olup, net marjı 2.8% dir.

Anahtar bilgiler

-5.9%

Kazanç büyüme oranı

-3.3%

EPS büyüme oranı

Healthcare Sektör Büyümesi	12.6%
Gelir büyüme oranı	6.4%
Özkaynak getirisi	7.3%
Net Marj	2.8%
Sonraki Kazanç Güncellemesi	05 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Henry Schein nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

LSE:0L3C Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
29 Jun 24	12,487	352	3,106
30 Mar 24	12,451	388	3,015
30 Dec 23	12,339	416	2,956
30 Sep 23	12,693	445	2,903
01 Jul 23	12,598	458	2,820
01 Apr 23	12,528	478	2,799
31 Dec 22	12,647	538	2,771
24 Sep 22	12,607	638	2,732
25 Jun 22	12,718	650	2,747
26 Mar 22	12,655	646	2,702
25 Dec 21	12,401	631	2,634
25 Sep 21	12,236	626	2,581
26 Jun 21	11,898	606	2,484
27 Mar 21	10,615	438	2,294
26 Dec 20	10,119	403	2,086
26 Sep 20	9,622	591	2,188
27 Jun 20	9,291	585	2,203
28 Mar 20	10,054	713	2,351
28 Dec 19	9,986	701	2,358
28 Sep 19	9,789	488	2,301
29 Jun 19	9,636	444	2,278
30 Mar 19	9,504	438	2,238
29 Dec 18	9,418	431	2,217
29 Sep 18	10,263	304	2,319
30 Jun 18	11,069	352	2,384
31 Mar 18	11,812	377	2,460
30 Dec 17	8,883	293	2,072
30 Sep 17	12,264	554	2,504
01 Jul 17	11,968	550	2,468
01 Apr 17	11,782	534	2,440
31 Dec 16	11,572	507	2,409
24 Sep 16	11,302	498	2,366
25 Jun 16	11,122	492	2,336
26 Mar 16	10,879	489	2,296
26 Dec 15	10,630	479	2,238
26 Sep 15	10,481	482	2,219
27 Jun 15	10,419	469	2,215
28 Mar 15	10,405	467	2,202
27 Dec 14	10,371	466	2,196
27 Sep 14	10,196	457	2,147
28 Jun 14	9,921	450	2,079
29 Mar 14	9,697	442	2,025
28 Dec 13	9,561	432	1,979

Kaliteli Kazançlar: 0L3C yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 0L3C 'nin mevcut net kar marjları (2.8%) geçen yılın (3.6%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 0L3C şirketinin kazançları son 5 yılda yılda 5.9% oranında azaldı.

Büyüme Hızlandırma: 0L3C 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: 0L3C geçtiğimiz yıl negatif kazanç büyümesine ( -23.2% ) sahipti ve bu da onu Healthcare sektör ortalamasıyla ( 17.7% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: 0L3C 'nin Özsermaye Getirisi ( 7.3% ) düşük olarak değerlendiriliyor.

Henry Schein Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Henry Schein, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Second quarter 2024 earnings released: EPS: US$0.81 (vs US$1.07 in 2Q 2023)

Henry Schein, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: EPS: US$0.72 (vs US$0.92 in 1Q 2023)

Henry Schein, Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings released: EPS: US$3.19 (vs US$3.95 in FY 2022)

Recent updates

Henry Schein, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Henry Schein, Inc.(NasdaqGS:HSIC) dropped from FTSE All-World Index (USD)

Insider recently sold US$1.5m worth of stock

Second quarter 2024 earnings released: EPS: US$0.81 (vs US$1.07 in 2Q 2023)

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

Henry Schein, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$0.72 (vs US$0.92 in 1Q 2023)

Henry Schein, Inc. to Report Q1, 2024 Results on May 07, 2024

Henry Schein, Inc. Announces Appointment of Members to the Company’S Executive Management Committee

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority interest in TriMed, Inc.

Henry Schein, Inc., Annual General Meeting, May 21, 2024

Insider recently sold US$478k worth of stock

Full year 2023 earnings released: EPS: US$3.19 (vs US$3.95 in FY 2022)

Henry Schein, Inc. Presents Comprehensive Lineup of Solutions At the 2024 Chicago Dental Society Mid Winter Meeting

Henry Schein, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire an unknown majority interest in TriMed, Inc.

Henry Schein Appoints Carole T. Faig as New Independent Director

Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

Henry Schein, Inc. Provides Earnings Guidance for 2023

Henry Schein, Inc. announced delayed 10-Q filing

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority stake in Shield HealthCare, Inc.

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year of 2023

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: US$1.07 (vs US$1.17 in 2Q 2022)

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire a majority stake in Shield HealthCare, Inc.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired a majority stake in Large Practice Sales LLC.

Henry Schein, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insider recently sold US$835k worth of stock

Executive VP recently sold US$1.9m worth of stock

Henry Schein, Inc. Provides Sales Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: EPS: US$0.92 (vs US$1.32 in 1Q 2022)

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) agreed to acquire SIN - Sistema de Implante Nacional S.A. from Southern Cross Group.

Independent Director recently sold US$148k worth of stock

Independent Lead Director recently sold US$504k worth of stock

Now 20% undervalued after recent price drop

Independent Director recently sold US$923k worth of stock

Full year 2022 earnings released: EPS: US$3.95 (vs US$4.51 in FY 2021)

Henry Schein, Inc. Reports Impairment Charge on Intangible Assets for the Fourth Quarter Ended December 31, 2022

Henry Schein, Inc. (NasdaqGS:HSIC) announces an Equity Buyback for $400 million worth of its shares.

Henry Schein, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Insider recently sold US$1.2m worth of stock

Henry Schein, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Henry Schein, Inc. Announces its Lineup of Products and Solutions At the American Association of Oral and Maxillofacial Surgeons (AAOMS) Annual Conference in New Orleans, La. from September 12 Through September 17

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Midway Dental Supply, Inc.

Henry Schein, Inc. Announces the Passing of Board Member E. Dianne Rekow

Second quarter 2022 earnings released: EPS: US$1.17 (vs US$1.11 in 2Q 2021)

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year 2022

Henry Schein, Inc. Appoints Mark Hillebrandt as Chief Digital Revenue Officer

Henry Schein, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Condor Dental Research Company SA from MCCB Holding Sarl.

Henry Schein, Inc.(NasdaqGS:HSIC) dropped from Russell 1000 Dynamic Index

Henry Schein, Inc. (NasdaqGS:HSIC) entered into a definitive agreement to acquire Condor Dental Research Company SA from MCCB Holding Sarl.

Insider recently sold US$982k worth of stock

Henry Schein, Inc. Appoints Dirk Benson as Chief Commercial Officer of North America Distribution Group

Henry Schein, Inc. Provides Earnings Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$1.32 (vs US$1.17 in 1Q 2021)

Henry Schein, Inc. to Report Q1, 2022 Results on May 03, 2022

Henry Schein Inc. Announces Executive Changes, Effective from July 1, 2022

Henry Schein Promotes Jennifer Ferrero to Corporate Secretary, Effective July 1, 2022

Executive VP recently sold US$2.0m worth of stock

Henry Schein to Showcase A Wide Portfolio of Products, Services, and Solutions During the Chicago Midwinter Dental Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Henry Schein, Inc. Provides Earnings Guidance for the Year 2022

Henry Schein, Inc. Announces Lineup of New Products and Solutions At the Greater New York Dental Meeting

Third quarter 2021 earnings released: EPS US$1.16 (vs US$1.00 in 3Q 2020)

Henry Schein, Inc. Announces Not to Provide Guidance for the Year 2021